Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Revenue Drivers
INCY logo

Incyte Corp Surges to $1.36B Q3 Revenue, Up 22%

INCY10-QFiling Date: 10/28/2025
Incyte Corporation
Description

What this story covers

Incyte Corp's Q3 2025 10-Q shows 22% revenue growth to $1.36B, driven by Jakafi and Opzelura sales, with net income up 299% to $424M. Pipeline advances in oncology and inflammation, strong $2.93B liquidity, but faces generic and reimbursement risks.

Story snapshot

CompanyIncyte Corporation
TickerINCY
VariantStandard detailed
Duration11:28
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0000879169-25-000118

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in